<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Human Disabled-2 (Dab2), a putative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene, is frequently down-regulated in human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This study aims to explore the association between Dab2 methylation status and expression in newly diagnosed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients and patients who received <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> (<z:chebi fb="0" ids="50131">decitabine</z:chebi>) treatment, so as to determine the effect of Dab2 in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Methylation-specific polymerase chain reaction and <z:chebi fb="0" ids="17137">bisulfite</z:chebi> sequencing were used to detect the methylation status of Dab2 gene </plain></SENT>
<SENT sid="3" pm="."><plain>Dab2 expression was investigated by using fluorescence quantitation RT-PCR (FQRT-PCR) and western blot analysis </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Hypermethylation of Dab2 gene was present in 50.6% of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and was significantly correlated with the down-regulation of Dab2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression </plain></SENT>
<SENT sid="5" pm="."><plain>There was a significant difference in methylation frequency between <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>/<z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> associated with isolated del (5q) (RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>/5q-) group (33.3%) and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts-1/-2 (<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e>/<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e>) group (73.3%) </plain></SENT>
<SENT sid="6" pm="."><plain>Significant difference was also observed between refractory cytopenia with multiline <z:mpath ids='MPATH_589'>dysplasia</z:mpath> group (37.8%) and <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e>/<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e> group </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, higher frequency of hypermethylation was observed in intermediate-2-/high-risk group, compared to low-risk/intermediate-1-risk group (75.0% vs. 40.0%) </plain></SENT>
<SENT sid="8" pm="."><plain>Demethylating agent <z:chebi fb="0" ids="50131">5-aza-2'-deoxycytidine</z:chebi> treatment could partly reverse hypermethylation and, hence, restore the expression of Dab2 gene </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The Dab2 gene is inactivated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in part by DNA methylation, and the suppression of Dab2 expression by DNA methylation may play a role in the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>